ANEW MEDICAL INC (WENA) Stock Price, Forecast & Analysis
USA - NASDAQ:WENA - US7580831094 - Common Stock
WENA Key Statistics, Chart & Performance
The current stock price of WENA is 0.726 USD. In the past month the price decreased by -30.86%.
WENA Latest News, Press Relases and Analysis
WENA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| HASI | HA SUSTAINABLE INFRASTRUCTUR | 12.04 | 3.97B | ||
| BUR | BURFORD CAPITAL LTD | 8.3 | 1.96B | ||
| ACTG | ACACIA RESEARCH CORP | 50.86 | 355.60M | ||
| SWKHL | SWK HOLDINGS CORP - SWKH 9 01/31/27 | 11.76 | 310.13M | ||
| SWKH | SWK HOLDINGS CORP | 7.59 | 199.99M | ||
| SUIG | SUI GROUP HOLDINGS LTD | 11.42 | 223.45M | ||
| MLCI | MOUNT LOGAN CAPITAL INC | N/A | 101.27M | ||
| FTFT | FUTURE FINTECH GROUP INC | N/A | 25.91M | ||
| SHFS | SHF HOLDINGS INC | N/A | 6.98M |
Related stock screener links
About WENA
Company Profile
ANEW Medical Inc is a US-based company operating in Financial Services industry. The company is headquartered in New York City, New York. The company went IPO on 2022-04-29. ANEW Medical, Inc. is a specialty pharmaceutical company. The firm specializes in the development of diagnostics and novel disease-modifying therapies for neurological and age-related disorders. The firm focuses on central nervous systems (CNS) diseases utilizing cell and gene therapies to mitigate age-related pathologies such as Alzheimer's disease (AD), dementia symptoms and neuromuscular diseases. The firm has exclusive worldwide rights to develop and commercialize product platforms based on its proprietary isoform transcribed from the human Klotho gene referred to as secreted Klotho or s-KL. This s-KL protein or gene therapy has been recognized for its potential to mitigate age-related pathologies such as ALS, Alzheimer's and Parkinson's Disease. Its lead gene therapy product candidates are AMI-101 (AAV9-CMV-sKL) for the treatment or prevention of Alzheimer’s disease, and AMI-202 (AAVmyo-Des-sKL) gene therapy product for treatment and prevention of Lou Gehrig’s disease.
Company Info
ANEW MEDICAL INC
1115 Broadway, 12th Floor
New York City NEW YORK US
Employees: 0
Phone: 16469165315
ANEW MEDICAL INC / WENA FAQ
Can you describe the business of ANEW MEDICAL INC?
ANEW Medical Inc is a US-based company operating in Financial Services industry. The company is headquartered in New York City, New York. The company went IPO on 2022-04-29. ANEW Medical, Inc. is a specialty pharmaceutical company. The firm specializes in the development of diagnostics and novel disease-modifying therapies for neurological and age-related disorders. The firm focuses on central nervous systems (CNS) diseases utilizing cell and gene therapies to mitigate age-related pathologies such as Alzheimer's disease (AD), dementia symptoms and neuromuscular diseases. The firm has exclusive worldwide rights to develop and commercialize product platforms based on its proprietary isoform transcribed from the human Klotho gene referred to as secreted Klotho or s-KL. This s-KL protein or gene therapy has been recognized for its potential to mitigate age-related pathologies such as ALS, Alzheimer's and Parkinson's Disease. Its lead gene therapy product candidates are AMI-101 (AAV9-CMV-sKL) for the treatment or prevention of Alzheimer’s disease, and AMI-202 (AAVmyo-Des-sKL) gene therapy product for treatment and prevention of Lou Gehrig’s disease.
What is the current price of WENA stock?
The current stock price of WENA is 0.726 USD. The price decreased by -0.55% in the last trading session.
Does ANEW MEDICAL INC pay dividends?
WENA does not pay a dividend.
What is the ChartMill technical and fundamental rating of WENA stock?
WENA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
WENA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to WENA.
WENA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to WENA. Both the profitability and financial health of WENA have multiple concerns.
WENA Financial Highlights
Over the last trailing twelve months WENA reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS decreased by -115.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -22.5% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |